Venatorx Pharmaceuticals Inc
Venatorx Pharmaceuticals Inc received −$1.1M in federal prime contract obligations in the 12 months ending Oct 5, 2026, down 1996.0% from $60K the year before, and $148.7M since FY2022. Its largest customer is the Department of Health and Human Services.
See 2 contracts ending in the next 18 months ↓Contractor details
- Unique Entity ID (UEI)
- MBBKNBU5DCC6
- CAGE code
- 61SY9
- Headquarters
- Malvern, PA
- Business size
- Small Business
As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year.
Top agencies
Funding agencies ranked by obligations since FY2022.
| Funding agency | Latest 12 mo | Since FY2022 |
|---|---|---|
| Department of Health and Human Services | −$676K | $149.2M |
Top NAICS codes
Industry codes agencies recorded on this contractor's awards, since FY2022.
| NAICS | Industry | Latest 12 mo | Since FY2022 |
|---|---|---|---|
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | −$615K | $121.7M |
| 541715 | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | $0 | $21.8M |
| 541711 | Research and Development in Biotechnology | −$521K | $5.2M |
What it sells
Product and service codes (PSC) on this contractor's awards, since FY2022.
| PSC | Description | Since FY2022 |
|---|---|---|
| 6505 | Drugs and Biologicals | $72.1M |
| AN13 | Health R&D services; Health Care services; Experimental Development | $49.6M |
| AN12 | Health R&D services; Health Care services; Applied Research | $27.5M |
Contracts ending in the next 18 months
This contractor's largest awards whose current period of performance ends soon. Options and extensions often move these dates.
| Award | Agency | Obligated | Current end |
|---|---|---|---|
| 75A50123C00050 | Department of Health and Human Services VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. | $20.3M | Dec 31, 2026 |
| 75N93020C00016 | Department of Health and Human Services TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | $21.8M | Jan 18, 2027 |
Recent awards
This contractor's newest prime contract awards, most recent first.
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| 75A50123C00050 | Department of Health and Human Services VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. | $20.3M | Sep 15, 2023 |
| 75A50122C00080 | Department of Health and Human Services VENATORX PHARMACEUTICALS: ANTIBIOTIC FOR AMR AND BIOTHREAT PATHOGENS | $72.1M | Sep 27, 2022 |
Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.